Videos

Dr Kuykendall's Perspective: Durable Hct Control in Patients With PV

Dr Kuykendall's Perspective: Durable Hct Control in Patients With PV
Hematologist-oncologist Dr Andrew Kuykendall discusses maintaining strict hematocrit (Hct) control and when it may be time to intervene with Jakafi.

Dr Kuykendall's Perspective: Hct Control and WBC Reduction in Patients With PV

Dr Kuykendall's Perspective: Hct Control and WBC Reduction in Patients With PV
Hematologist-oncologist Dr Andrew Kuykendall shares how he manages progressive white blood cell (WBC) counts and when it may be time to intervene with Jakafi.

Dr Kuykendall's Perspective: Controlling Hct and Assessing Symptoms in Patients With PV

Dr Kuykendall's Perspective: Controlling Hct and Assessing Symptoms in Patients With PV
Hematologist-oncologist Dr Andrew Kuykendall details how he uncovers symptoms in patients with PV, and when it may be time to intervene with Jakafi.

Mechanism of Action of Jakafi
Mechanism of Action of Jakafi
Hematology specialist Dr Harry Erba reviews the mechanism of action of Jakafi, a JAK1 and JAK2 inhibitor, highlighting how Jakafi works to inhibit overactive JAK pathway signaling. Dr Erba also discusses... Read More

Dosing of Jakafi in Patients With PV Who Have Had an Inadequate Response to or Are Intolerant of HU
Dosing of Jakafi in Patients With PV Who Have Had an Inadequate Response to or Are Intolerant of HU
Hematology specialist Dr Harry Erba discusses the appropriate dosing of Jakafi in patients with... Read More